|
Characteristics
|
ER-negative patients who received chemotherapy
|
Percent
|
ER-negative patients who did not receive chemotherapy
|
Percent
|
ER-positive patients who received chemotherapy
|
Percent
|
|---|
|
Number of patients
|
1499
|
100.00
|
835
|
100.00
|
3151
|
100.00
|
|
Age at diagnosis (mean ± SD, years)
|
51.69 ± 10.85
|
59.46 ± 12.18
|
51.74 ± 9.88
|
|
Family history
| | | | | | |
|
No
|
974
|
64.98
|
457
|
54.73
|
2233
|
70.87
|
|
Yes
|
275
|
18.35
|
148
|
17.72
|
596
|
18.91
|
|
Missing
|
250
|
16.68
|
230
|
27.54
|
322
|
10.22
|
|
Tumor stage
| | | | | | |
|
1
|
356
|
23.75
|
401
|
48.02
|
606
|
19.23
|
|
2
|
804
|
53.64
|
259
|
31.02
|
1751
|
55.57
|
|
3
|
182
|
12.14
|
58
|
6.95
|
526
|
16.69
|
|
Missing
|
157
|
10.47
|
117
|
14.01
|
268
|
8.51
|
|
Histological grade
| | | | | | |
|
Well-differentiated
|
23
|
1.53
|
97
|
11.62
|
390
|
12.38
|
|
Moderately differentiated
|
293
|
19.55
|
310
|
37.13
|
1624
|
51.54
|
|
Poorly/undifferentiated
|
1183
|
78.92
|
428
|
51.26
|
1137
|
36.08
|
|
Tumor size
| | | | | | |
|
≤2 cm
|
664
|
44.30
|
528
|
63.23
|
1387
|
44.02
|
|
≥2 cm to ≤5 cm
|
744
|
49.63
|
271
|
32.46
|
1490
|
47.29
|
|
≥5 cm
|
91
|
6.07
|
36
|
4.31
|
274
|
8.70
|
|
Lymph node status
| | | | | | |
|
Negative
|
735
|
49.03
|
651
|
77.96
|
976
|
30.97
|
|
Positive
|
764
|
50.97
|
184
|
22.04
|
2175
|
69.03
|
|
PR status
| | | | | | |
|
PR-negative
|
1271
|
84.79
|
633
|
75.81
|
546
|
17.33
|
|
PR-negative HER2-negative
|
692
|
46.16
|
315
|
37.72
|
304
|
9.65
|
- Results are presented as number of patients unless stated otherwise. BCAC, Breast Cancer Association Consortium; ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation; HER2, human epidermal growth factor receptor 2.
